الفهرس 
Prognostic value of RGS1 and mTOR Immunohistochemical Expression in Multiple Myeloma Patients
AbstractOnly 14 pages are availabe for public view
 |  | from | 189 |  |  |
| | | from | 189 | | |
Abstract
Background: Plasma cell myeloma is a clonal proliferative disorder of terminally
differentiated B-cell resulting in the accumulation of neoplastic plasma cells in the bone
marrow. RGS1 may play an important role in the pathophysiology of MM or plasma cells
with an increase RGS1 gene expression in Multiple myeloma neoplasm. mTOR signaling
dysregulation has been identified in patients diagnosed with a number of human cancers,
including multiple myeloma and has become a target for treatment in an effort to increase
overall survival.
Aims: to evaluate the IHC expression of RGS1 and mTOR markers and their relation to the
clinical parameters as well as other diagnostic parameters. Also, to estimate the prognostic
value of RGS1 and mTOR expression in multiple myeloma patients and find out the relation
between expression of these markers at time of diagnosis and the response to treatment as
well as OS of the patients.
Patients and Methods: The present study included 44 denovo Multiple Myeloma cases. The
patients were recruited from the Medical Oncology Department, National Cancer Institute,
Cairo University. Detection of RGS1 and mTOR expression was performed using
Immunohistochemical staining on bone marrow biopsy samples.
Results: The median age was 51 years with male to female ratio 1.58:1.There was a highly
statistically significant association between mTOR and RGS1 expression with LDH (P
<0.001 and P <0.001 respectively). Also, there was a borderline statistically significant
association between mTOR expression and FLC (P value= 0.074). Regarding the association
between mTOR and RGS1 expression with the response to treatment, there was a highly
statistically significant association (P <0.001 and P <0.001 respectively). Moreover, there
was a positive highly statistically significant correlation between mTOR expression and
RGS1 expression among all studied cases (P-value <0.001).Finally, there was a significant
influence of mTOR and RGS1expression on overall survival probability (p value <0.001 and
<0.001 respectively) with better survival for those having low expression.
Conclusion: In MM patients, RGS1 and mTOR over expression successfully identifies
patients with bad prognosis. Their overexpression is suggested as the markers associated with
a low complete remission, and shorter survival